Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saroglitazar vs Vitamin E in NAFLD/NASH
NCT04193982Phase 3Unknown
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Jan 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of saroglitazar in non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Asian Institute of Gastroenterology. Primary endpoint: Change in Non alcoholic fatty liver fibrosis score at 24 weeks. Status: unknown.
02
Drugs
saroglitazar
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04193982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193982.